Lawmakers are already gunning for more dramatic drug pricing reforms

Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.

By Karissa Waddick • Aug. 31, 2023

Finding the right flu vaccine is hard. Getting people to take it is harder.

Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.

By Michael Gibney • Aug. 30, 2023

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Medicare named the first 10 drugs up for negotiation. Now what?

The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

By Karissa Waddick • Aug. 30, 2023

Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’

FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages. 

By Karissa Waddick • Aug. 25, 2023

‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

By Michael Gibney • Aug. 24, 2023

A rare disease researcher aims to tackle disability discrimination in new lawsuit

How a pediatric neurologist is advocating for herself and the disabled community in a legal battle with the Howard Hughes Medical Institute.

By Alexandra Pecci • Aug. 22, 2023

A leading Democrat reveals how his mental health struggles shape his policy approach

Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.

By Karissa Waddick • Aug. 17, 2023

Pharma’s rare disease rush

Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?

By Meagan Parrish , Karissa Waddick • Aug. 14, 2023

PBMs could soon feel the regulatory sting

From Congress to the FTC to state legislatures, regulators are cracking the whip against PBMs.

By Karissa Waddick • Aug. 4, 2023

Big Pharma CEOs get candid about pricing and M&A

Head honchos at the biggest pharma companies reporting second-quarter earnings dig into the topics du jour.

By Michael Gibney • July 28, 2023

Biosimilar makers split strategies in bid to take on top-selling Humira

In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

By Jonathan Gardner • July 26, 2023

With OTC birth control approved, access battles have just begun

Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

By Karissa Waddick • July 26, 2023

For Merck, understanding maternal mortality is the first step toward equity

Merck has invested for more than a decade in reducing maternal death rates in the U.S. and globally. Now for the next chapter.

By Michael Gibney • July 25, 2023

4 controversial measures in Congress’ pandemic preparedness bill

Efforts to tackle drug pricing, shortages, the speed of FDA approvals and more have been mixed into Congress’ efforts to reauthorize the Pandemic and All Hazards Preparedness Act.

By Karissa Waddick • July 20, 2023

DCTs create fresh privacy challenges for review boards. Now there are guidelines.

A new toolkit developed by industry stakeholders paves the way for faster reviews.

By Kelly Bilodeau • July 17, 2023

FDA’s upcoming psychedelic review looms large for a budding industry

A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.

By Karissa Waddick • July 12, 2023

Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

By Michael Gibney • July 7, 2023

Pharma’s strike-from-all-sides attack on the IRA could be decided by the Supreme Court

New lawsuits challenging the Inflation Reduction Act’s price negotiation program hit the government with multiple Constitution-based challenges.

By Alexandra Pecci • July 6, 2023

A BMS exec’s journey around the world in 90 days

As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.

By Karissa Waddick • July 5, 2023

The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

Intercept’s NASH retreat is the latest setback for a challenging liver disease

Intercept Pharmaceuticals has stepped out of the race to the first U.S. approved treatment for the complicated liver disease NASH, leaving room for other pharmas to get their foot in the door.

By Michael Gibney • June 27, 2023

The spotlight is on accelerated approvals — now FDA could run a tighter ship

As the fallout of the Aduhelm approval continues, scrutiny of the speedier pathway has increased and the pressure is on to close a key gap in the regulation.

By Kelly Bilodeau • June 20, 2023

Shaking up pharma: Change that leaders would like to see

Industry execs give voice to the “game changers” they believe would have the greatest impact on the healthcare ecosystem for all.

By Taren Grom • June 16, 2023

How pharma execs are approaching drug pricing and other quandaries

From implementation of the Inflation Reduction Act, to the looming patent cliff and more, pharma leaders have a lot on their plates.

By Karissa Waddick • June 16, 2023

Why cancer could be the ideal realm for psychedelic treatments

The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.”

By Meagan Parrish • June 9, 2023